Clinical Trial Update: mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating mFOLFIRINOX versus mFOLFOX with or without nivolumab for HER2-negative advanced, unresectable, or metastatic esophageal, gastroeso…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• mFOLFIRINOX
• mFOLFOX
• nivolumab (nivolumab)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma | Phase 3 | Status: RECRUITING